版本:
中国

Celgene quarterly profit rises 17.5 percent

April 27 U.S. biotechnology company Celgene Corp reported a 17.5 percent jump in quarterly net income on Thursday, helped by demand for its flagship multiple myeloma drug Revlimid.

The company's net income rose to $941 million, or $1.16 per share, in the first quarter ended March 31, from $801 million, or 99 cents per share, a year earlier.

Total revenue rose to $2.96 billion from $2.51 billion. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐